SUBSCRIBERS
Biolidics issues letter of demand to biochip partner Sysmex over IP matters
Add BT as a preferred source
Vivienne Tay
Published Mon, Oct 19, 2020 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.
Biolidics has issued a letter of demand to Japan-based healthcare group Sysmex Corporation, saying that Sysmex breached IP obligations under a collaboration agreement struck in 2016 for the joint development of biochips.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
